Table 2.
All patients (n = 55) | |
---|---|
Objective response rate, n (% [95% CI]) | 27 (49 [35–63]) |
Best overall response, n (%) | |
Complete response | 12 (22) |
Partial response | 15 (27) |
Stable disease | 4 (7) |
Progressive disease | 16 (29) |
Nonevaluablea | 2 (4) |
No assessmentb | 6 (11) |
BICR blinded independent central review, CI confidence interval, RECIST v1.1 Response Evaluation Criteria in Solid Tumors, version 1.1
aIncludes patients who had postbaseline assessments available but were not evaluable
bIncludes patients who had a baseline assessment but no postbaseline assessment at data cutoff